Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of luspatercept vs placebo in transfusion-dependent beta-thalassemia
2015-003224-31Phase 3Unknown
- Sponsor
- Celgene Corporation
- Start
- Nov 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in beta thalassemia comparing Luspatercept plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2015-003224-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003224-31.